The specificity of VTP-50469 against KMT2A-rearranged leukemia was further reinforced by its inability to significantly delay the progression of a BCR::ABL1 fusion-positive ALL PDX (Krivtsov et al., 2019). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.